Viewport Meta

IPhone / Mobile Compatible

Microsoft

Microsoft Azure

Digital Ocean

Next.js

Microsoft Azure US East Region

Cloudinary

Managing Director and Chief Financial Officer

Greg Mann

Chief Executive Officer

Mark Pacyna

VP, Clinical & Regulatory Affairs

Arslan Malik

Director of Quality

Jacob Davis

Healthcare

Don Hefner

Sr. Development Engineer

Eric Conley

Board Member

Ethan Benovitz

Sr. Manufacturing Technician

Jeff Dulude

Engineering

Megha Shah

Development Engineer I

Sierra Raskevitz

Hanson Gifford

Andrew Halpert

Chief Technology Officer

United States Early Stage Companies (Top 10K)

Lightstone Ventures Portfolio Companies

Medical Device Companies With Fewer Than 50 Employees (Top 10K)

New England Startups

Reprieve Cardiovascular is a pioneering medical device company focused on innovative fluid management technologies for congestive heart failure. The company's Reprieve technology is being investigated as an innovative fluid management treatment. Providing clinicians with the ability to precisely control a patient’s fluid volume may both enable improved cardiac care, as well as, be instrumental in the decongestion of acutely decompensated heart failure patients (ADHF). Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are subsidiaries of parent company CardioRenal Systems, Inc.

Lightstone Ventures

Sante Ventures

Series A - Reprieve Cardiovascular

Venture Round - Reprieve Cardiovascular

Deerfield

Abiomed

Milford

Massachusetts

United States

North America

Reprieve Cardiovascular

New Medtech Company: Reprieve Cardiovascular Wants to Bring Intelligent Fluid Management to Heart Failure Patients

New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure ...

Reprieve Cardiovascular Emerges From Stealth Mode With $42M Financing

Reprieve Cardiovascular Raises $42M in Series A Financing

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid ...

Reprieve emerges from stealth with $42M for heart failure treatment

Elie Brender on LinkedIn: Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series…

A system designed to personalize decongestion management and safely remove fluid to improve patient outcomes and prevent hospital readmissions for patients with acute decompensated heart failure.

An automated fluid management system that tailors diuretic dosing to speed fluid removal and symptom relief while preventing hypotension and maintaining renal function.

A therapy designed to manage fluids during diuretic treatment for acute decompensated heart failure, enabling precise and predictable fluid level management to improve diuretic efficiency and patient outcomes.

A clinical trial comparing decongestive therapy administered by the Reprieve System to optimized diuretic therapy in treating patients with acute decompensated heart failure.

India

Asia

Reprieve Cardiovascular, Inc. is a medical device company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment. The company is developing innovative therapies to improve the lives of heart failure patients worldwide.

Reprieve Cardiovascular, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 7, 2024 4:25 AM	ac0bb9b5
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 7, 2024 4:25 AM	705a1b04
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	959f7b6a
crunchbase profile	general	Nov 25, 2024 9:42 AM	8e5465e9
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 1:52 PM	9255e3cb
peers	general
news basic	general	Mar 7, 2024 4:25 AM	3b1a860f
bundesanzeiger	filings
financials download nd	financials
private financials	financials

REPR

COM:REPRIEVECARDIO

Reprieve Cardiovascular, Inc.